 |
| |
 R&D Innovation & Strategies –Integrated Strategies To Over Come Pitfalls, Enhance Drug Discovery, Overcome Attrition & New Prediction Tools That Drive Clear Decision Making.
Focused Sirna Screens In Disease Based Assays - The Fast Track To A Target
Non-Invasive, Label-Free Assays - Getting the Most Out of your Targets and a Handle on Off-Target Effects
In Silico Innovation To Solve Drug Discovery – In-Silico Data, Data Mining, Predictive Modeling,
Exploring the impact & success rate of HTS Compound Library Screening.
Partnerships, Alliances & Outsourcing –Successful Partnerships, Managing Alliances, Balancing Conflicting Interests, Biotech Technology Platforms
Intergration of technologies & applications to bridge the gap between discovery, validation & development
How do you create intelligence from all this data, both structured and unstructured, across the entire value chain?
Streamline data processes and integration whilst improving early decision making and lowering attrition through the benefit of developing a dynamic workflows and an efficient infrastructure.
“An innovative approach”-lean/ 6-sigma efforts and organisational structures supporting lead optimisation."
Alternative cost effective screening methods and techniques to strengthen assay effectively. Bringing in-vitro screening for HTS, hit optimisation & lead optimisation together.
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
 |
Lee E. Babiss, Ph.D.
Head, Global Pharma Research Roche
Basel, Switzerland
Lee E. Babiss, Ph.D., is Global Head, Pharma Research at Roche in Basel Switzerland where he is responsible for leading and managing Research within Roche Pharma across the five Disease Biology Areas: virology (Palo Alto, California), oncology (Nutley, NJ), metabolic diseases (Basel, Switzerland), inflammation (Palo Alto), and central nervous system (Basel), as well as research in Shanghai, China. Babiss is also a member of the Roche Pharma Executive Committee, Strategic Portfolio Committee and Chairs the Roche R&D Center China Scientific Board.
Prior to July 2007, Babiss was vice president, Preclinical Research and Development for Roche in Nutley, N.J., where he was responsible for developing and directing oncology, metabolic diseases and inflammation research strategy. As a member of the International Research Management Team, he was involved in developing global research strategy, and Chaired the Roche Biomarker Leadership Team, a cross-divisional effort within the pharmaceuticals and diagnostics divisions that develops and implements the company’s biomarker strategy.
Prior to joining Roche, Babiss was vice president of Biological Sciences and Genetics at Glaxo Wellcome where he focused on the development of antisense technology and cancer therapeutics, headed the Department of Molecular Cell Biology, and played a key role developing and implementing the Cell Cycle Program. Babiss was also a member of the U.S. Research Senior Management Team, which formulated and implemented Glaxo’s U.S. research strategy and was involved in creating the Glaxo Wellcome Corporate Genetic Strategy, which led to the creation of the company’s Genetics Division.
Babiss attended graduate school at Columbia University, College of Physicians and Surgeons, in New York, where he earned his Ph.D. in Microbiology in 1982 studying DNA tumor viruses. He then began his postdoctoral career at the Rockefeller University in New York where he studied the molecular regulation of hepatocyte gene expression. Later, Babiss was promoted to assistant professor in Cell Biology, studying adenovirus genetics.
An author on more than 70 publications, Babiss currently serves on the board of the Center for Advanced Biotechnology and Medicine at UMDNJ, the Finance Board of the American Society of Microbiology, the Biotechnology Industry Organization, the Scientific Board of the Pharmaceutical Research and Manufacturers of America, and the R&D Council of New Jersey |
|
|
 |
|
|
|
|
|
|
| |
 |
Steve Street.
Vice President for Research,
Head of Research Centers of Emphasis,
Head of Pfizer R&D Continuous Improvement
Steve Street joined Pfizer in 1985 and held a variety of roles within the Chemistry Department in Sandwich UK, before being appointed Head of Chemistry for Sandwich Discovery in 2001. Three years later, at the start of 2004, Steve moved to establish and lead the Chemistry Discipline across Worldwide Discovery. Steve held this role through to early 2007 when he was delighted to be asked to take on a new role as Head of the Research Centers of Emphasis, covering a range of activities supporting Worldwide Research including External Research, BioImaging, Computational Sciences and High Throughput Screening. In April 2008, Steve was asked to become Head of Continuous Improvement across Pfizer Research and Development covering Project start through to Proof of Concept delivery in Patients.
Outside of his work, Steve enjoys time with his family, risking life and limb on his roller blades, and cutting his hands to shreds looking after his rose garden. |
|
|
|
|
|
|
|
|
| |
 |
Eric Trinquet
Head of Technology &
Chemistry, Cisbio Bioassays
Mr Eric Trinquet obtained his DUT in biological and biochemical analysis from the Institut Universitaire de Technologies of Montpellier (France). He joined Cisbio in 1990, and was very early involved in new technologies for drug discovery. He was instrumental in developing Cisbio international’s proprietary HTRF® technology. Since 2007, Eric has managed Cisbio’s Technology and Chemistry Group, supervising a team of research scientists and students in developing fluorescence methodologies and assays, and determining their use in life sciences, in particular in the field of GPCR investigation and screening. |
|
|
|
|
|
|
|
| |
 |
Dr. Mario Albrecht
Head of Research Group for Molecular
Networks in Medical Bioinformatics
Max Planck Institute for Informatics,
Saarbrücken, Germany
Since 2006 Dr. Mario Albrecht heads the research group for molecular networks in medical bioinformatics (http://www.medbioinf.de) at the Max Planck Institute for Informatics, Saarbrücken, Germany. His research focus lies on the development and application of bioinformatics methods for computational systems biology and medicine. He is particularly interested in integrating and analyzing large-scale datasets as well as modeling and predicting biological processes and their dysfunction in disease. Recent work has concentrated on prioritizing candidate disease genes and understanding the function of protein interactions and alternative splicing. Some of the diseases studied in cooperation with medical researchers are inflammatory bowel disease, neurodegenerative disorders, and viral infections.
Dr. Mario Albrecht studied computer science and bioinformatics at the University of Passau, Germany, and the University of Manchester, United Kingdom. In 1999 he received his master degree from the University of Manchester. In 2006 he obtained his PhD in bioinformatics from the Saarland University, Germany. From 1999 to 2002 he worked as research scientist for bioinformatics at the Fraunhofer Institute for Algorithms and Scientific Computing, St. Augustin, Germany. Since 2002 he performs research at the Max Planck Institute for Informatics, Saarbrücken, Germany, and is author of over 50 publications. |
|
|
|
|
|
|
|
| |
 |
Theodore J. Torphy, Ph.D.
Chief Scientific Officer & Head
External Research & Early Development
Johnson & Johnson Pharmaceuticals Group
Ted Torphy is Chief Scientific Officer and Head of External Research & Early Development (eRED) for Johnson & Johnson’s Pharmaceuticals Group. The eRED is responsible for building and managing a portfolio of external venture partner and pharmaceutical R&D collaborations on product and technology opportunities that are of strategic interest to Johnson & Johnson. Before assuming his current role in 2007, Ted was Corporate Vice President & Head of the Corporate Office of Science & Technology, a corporate function that identifies transformational healthcare technologies for all of Johnson & Johnson’s business sectors. Ted joined COSAT in 2003 after spending three years at Centocor, the biopharmaceutical arm of J&J, where he was Senior Vice President for Discovery and Preclinical Development.
Prior to joining Centocor, he spent 17 years with SmithKline Beecham, most recently as Vice President of Research for the Cardiovascular, Pulmonary and Metabolic Diseases. He is the author of more than 120 journal articles, review articles, book chapters, and patents. He serves on the editorial advisory boards of eight scientific journals, chairs the Board of Directors of the Cystic Fibrosis Therapeutics, Inc., and is a board member of several other non-profit academic, research, greenhouse and venture organizations. Ted holds a B.S. degree in Pharmacy from the University of Wisconsin and a Ph.D. in Pharmacology and Toxicology from West Virginia University. He completed his postdoctoral training at the University of California, San Diego. |
|
|
|
|
|
